促红细胞生成素拟肽研究进展  

Research progress in erythropoietin mimetic peptides

作　　者：董艳[1,2] 徐为人[1] 孔德新[2] 

机构地区：[1]天津药物研究院天津市新药设计与发现重点实验室,300193 [2]天津医科大学药学院

出　　处：《天津医药》2015年第1期102-105,共4页Tianjin Medical Journal

基　　金：天津市应用基础及前沿技术研究计划(12JCYBJC18800)

摘　　要：促红细胞生成素(Epo)是一种主要由肾脏合成并且分泌的活性糖蛋白,可刺激骨髓造血,主要用于治疗慢性肾功能衰竭导致的贫血性疾病,Epo口服不吸收,需静脉注射给药。由于其在人体内的生物半衰期较短,需要频繁注射,给患者在使用过程中带来很多不便并造成一定的经济负担。因此,开发疗效好、不良反应小且持续时间长的Epo一直是研究热点,目前市场上出现了多种新型的促红细胞生成素类药物,其中Epo拟肽的相关研究一直备受人们的关注,本文综述了近年来有关Epo拟肽类药物的研究情况。Erythropoietin （EPO） is an active glycoprotein synthesized by kidney. The physiological function of regulat？ing the synthesis of erythrocytes by EPO makes it as a clinical drug for treatment of anemia resulted from chronic kidney fail？ure. However, its short biological half-life makes frequent administration, which limits its wide clinical utility since the tough burden and pain on patients. Therefore, the development of EPO derivatives with good efficacy, less adverse reaction and long duration has been a hot spot in the field during several decades. There are currently many different variants of EPO derivatives including erythropoiesis stimulating agents （ESAs） on the market. This article aims to summarize the recent re？search progress in the development of erythropoietin derivatives, specially focusing on EPO mimetic peptides （EMP）.

关 键 词：红细胞生成素 红细胞生成素 重组 受体 红细胞生成素 贫血 促红细胞生成素拟肽 

分 类 号：R556[医药卫生—血液循环系统疾病]